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In Brief
Hypoxia-inducible factors (HIFs) maintain
glioma stemness, and stem-like glioma
cells have an amplified hypoxic response
compared to bulk tumor cells. Johansson
et al. show that the glioma stem cell
marker CD44 is activated under hypoxia
and interacts with HIF-2a to enhance the
hypoxic and pseudo-hypoxic phenotype
of glioma stem cells.
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Hypoxia-inducible factors enhance glioma stem-
ness, and glioma stem cells have an amplified hypox-
ic response despite residing within a perivascular
niche. Still, little is known about differential HIF regu-
lation in stem versus bulk glioma cells. We show that
the intracellular domain of stem cell marker CD44
(CD44ICD) is released at hypoxia, binds HIF-2a (but
not HIF-1a), enhances HIF target gene activation,
and is required for hypoxia-induced stemness in
glioma. In a glioma mouse model, CD44 was
restricted to hypoxic and perivascular tumor regions,
and in human glioma, a hypoxia signature correlated
with CD44. The CD44ICD was sufficient to induce
hypoxic signaling at perivascular oxygen tensions,
and blocking CD44 cleavage decreased HIF-2a
stabilization in CD44-expressing cells. Our data indi-
cate that the stem cell marker CD44 modulates the
hypoxic response of glioma cells and that the
pseudo-hypoxic phenotype of stem-like glioma cells
is achieved by stabilization of HIF-2a through inter-
action with CD44, independently of oxygen.
INTRODUCTION
Glioblastoma multiforme (GBM), the highest-grade glioma and
deadliest brain tumor, responds well to surgery and irradiation
but invariably recurs as incurable treatment-resistant disease
(Huse and Holland, 2010). Resistance has been linked to the
presence of stem-like tumor cells located primarily in a perivas-
cular niche (PVN) (Hambardzumyan and Bergers, 2015), identi-
fied by expression of stem cell markers like CD133 (Singh et al.,
2003) or CD44 (Anido et al., 2010). Few viable strategies targeting
such stem-like glioma cells have been identified, in part because
most known drivers of stemness are essentially non-druggable
transcription factors like the hypoxia-inducible factors (HIFs).
Solid tumors frequently develop areas of hypoxia due in part to
tumors outgrowing the vascular supply and in part to tumor
vasculature malfunctioning (Semenza, 2012). This is particularlyCell Re
This is an open access article undtrue for GBMs, as one hallmark pathognomonic feature of GBMs
is pseudopalisading necrosis with surrounding hypoxia (Huse
and Holland, 2010). The cellular response to hypoxia is primarily
driven by two transcription factors: the oxygen-regulated HIF-1a
and HIF-2a. The HIFs regulate numerous pathways and
processes, including angiogenesis and a metabolic switch to-
ward anaerobic glycolysis (Semenza, 2012). In tumors, the hyp-
oxic response frequently also induces dedifferentiation of tumor
cells toward stem-like states. HIF expression has been linked to
enhanced stemness in glioma, and glioma stem cells display an
amplified hypoxic response, sometimes despite a perivascular
localization (Bar et al., 2010; Heddleston et al., 2009; Li et al.,
2009; Seidel et al., 2010; Soeda et al., 2009). While HIF-1a and
HIF-2a share regulation by oxygen and the majority of target
genes, it appears that HIF-2a is the primary driver of this hypox-
ia-induced dedifferentiation, as well as of pseudo-hypoxic
phenotypes of apparently well-vascularized stem-like glioma
cells (Pietras et al., 2010). Little is known about the differential
regulation of HIF-a subunits in stem-like versus tumor bulk cells
in glioma and other solid tumor types.
We previously found that the stem cell marker CD44 is specif-
ically expressed in the PVN of proneural GBM and that its cleav-
age by gamma-secretase can release an intracellular domain
(CD44ICD) capable of enhancing target gene activation by
HIFs (Pietras et al., 2014). Here, we investigate the role of
CD44 in regulation of hypoxic and pseudo-hypoxic phenotypes
of human and murine glioma cells. We demonstrate that CD44
cleavage is enhanced at hypoxia and that pharmacological inhi-
bition of this cleavage attenuates the hypoxic response. Inhibi-
tion of CD44 cleavage resulted in decreased HIF-2a, but not
HIF-1a, levels at hypoxia, and CD44ICD interacted specifically
with HIF-2a, resulting in enhanced HIF target activation at both
hypoxic and perivascular oxygen tensions. In murine GBM
in vivo, CD44 was specifically located in a perivascular, well-
oxygenated niche characterized by pseudo-hypoxic, HIF-
2a-positive, stem-like cells, as well as in a perinecrotic, hypoxic
niche characterized by HIF-1a- and HIF-2a-positive glioma cells.
Expression of CD44 and enzymes responsible for CD44ICD
generation correlated positively with a hypoxia gene signature
in the human GBM The Cancer Genome Atlas (TCGA) dataset,
and inhibition of CD44 cleavage diminished hypoxia-induced
stem cell characteristics and induced differentiation of primaryports 20, 1641–1653, August 15, 2017 ª 2017 The Author(s). 1641
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
glioma cells. Our data highlight differential regulation of HIF-a
subunits in stem-like tumor cells.
RESULTS
CD44 Expression and Cleavage Is Enhanced at Hypoxia
in Glioma
High-grade gliomaswere generated using the RCAS/tv-a system
to expressPDGFB and small hairpinRNA (shRNA) targeting Tp53
in nestin-expressing cells of neonatal Ntv-a Ink4a/Arf/ mice
(Holland et al., 1998; Shih et al., 2004). Tumors were stained for
CD44 and the neural stem cell marker nestin to identify stem-
like GBM cells and the PVN in vivo. As previously reported (Pie-
tras et al., 2014), CD44 staining was intensely present in the
PVN, where CD44 and nestin expression overlapped (Figure 1A).
Interestingly, while the bulk of the tumor was negative for CD44
staining, CD44 was also specifically enriched in hypoxic,
CAIX-expressing, perinecrotic (PN) cells, indicating that CD44
regulation of hypoxic signaling could occur in vivo (Figure 1A).
PDGFB-induced glioma primary cultures (PIGPCs) were isolated
from tumors and subjected to culture under normoxic (21%
oxygen [O2]) or hypoxic (1% O2) conditions. CD44ICD is gener-
ated from full-length CD44 in a two-step cleavage process
mediated by ADAM10/17 (to generate the membrane-bound
COOH-terminal fragment of CD44 [CD44EXT]), then gamma-
secretase (to generate CD44ICD) (Nagano and Saya, 2004).
CD44ICD generation was significantly enhanced by hypoxia in
PIGPCs (Figure 1B). Similarly, CD44EXT and CD44ICD levels
were both increased in human U251MG glioma cells cultured at
hypoxia (Figure 1C), whereas full-length CD44 protein and
CD44 mRNA levels were largely unaffected by hypoxia in both
human and murine glioma cells (Figures 1B, 1C, S1A, and S1B).
Band identities were confirmed by positive (TPA-induced cleav-
age) and negative (TPA plus the gamma-secretase inhibitor
DAPT to inhibit CD44EXT-to-ICD cleavage) controls (Figure 1C).
Themarked increase inCD44EXT followinggamma-secretase in-
hibition suggests that CD44ICD generation is underestimated by
quantifying the band corresponding toCD44ICD, likely due to the
short half-life of gamma-secretase-generated ICDs (Figure 1C).
To confirm the increase in intracellular CD44 at hypoxia, we
stained U251MG cells cultured at normoxia or hypoxia with an
antibody recognizing the C-terminal end of CD44. Staining re-
vealed primarily membrane-bound CD44 at normoxia and both
membrane-bound and intracellular CD44 at hypoxia (Figure 1D).
Quantitative image analysis of fluorescent images confirmed that
there was no significant difference in the membrane of cells, but
a significant increase in intracellular/cytoplasmic CD44 at hyp-
oxia was found (Figure 1D). Finally, staining PDGFB-induced
murine gliomas with the C-terminal CD44 antibody revealed an
intracellular staining pattern in addition to membrane staining
in PN tumor areas (Figure 1E). Together, these data show
enhanced CD44 cleavage into CD44ICD and increased intracel-
lular CD44 expression in hypoxic glioma cells in vitro and in vivo.
ADAM17 Expression Is Induced at Hypoxia in Glioma,
and ADAM Inhibition Blocks CD44 Cleavage
We speculated that the increased CD44ICD generation at hyp-
oxia could reflect increased activity of the enzymes responsible1642 Cell Reports 20, 1641–1653, August 15, 2017for cleavage (i.e., ADAM10 and/or ADAM17). Western blot anal-
ysis showed increased levels of mature ADAM17, but not
ADAM10, protein in hypoxic U251MG cells (Figure 2A). The
increased protein levels were associated with a modest but sig-
nificant increase in ADAM17 (but not ADAM10)mRNA levels after
prolonged exposure to hypoxia (Figure 2B). In murine gliomas
in vivo, ADAM17 expression was restricted to a subset of cells
and overlapped with CD44 expression in hypoxic tumor areas
(Figure 2C). In support of these observations, analysis of data
from the Allen Institute for Brain Science Ivy Glioblastoma Atlas
Project (Ivy GAP) showed significantly higher expression of
ADAM17 in microdissected PN tumor areas than in tumor bulk
(Figure 2D; p < 0.01, Tukey’s HSD test). To test whether the
induction of ADAM17 at hypoxia was dependent on HIFs, we
used small interfering RNA (siRNA) to knock down HIF1A and
HIF2A, respectively, in U3065MG cells cultured at hypoxia.
Targeting HIF2A, but not HIF1A, significantly diminished the
hypoxic induction of mature ADAM17 protein (Figure 2E). Finally,
to test whether ADAMs were indeed responsible for CD44 cleav-
age, we employed three structurally independent pharmacolog-
ical inhibitors of ADAM activity: TAPI-2, TMI 1, and GI 254023X.
All three inhibitors reduced CD44EXT levels (Figure 2F), suggest-
ing that induced ADAM17 activity could be responsible for
increased CD44ICD levels at hypoxia.
ADAM Inhibition Modulates the Hypoxic Response of
Glioma Cells
In light of our recent finding that CD44ICD can signal to enhance
HIF activity, our data suggest that CD44 cleavage at hypoxia
could represent a mode of tuning the hypoxic response in glioma
cells. We used the pharmacological ADAM inhibitors to deter-
mine whether CD44ICD release at hypoxia can affect the hypox-
ic response. Treating PIGPCs, T98G human glioma cells, or
U251MG human glioma cells with TAPI-2 indeed resulted in
significantly decreased activation of hypoxia responsive ele-
ments (HREs) at hypoxia, as measured by luciferase assay (Fig-
ures 3A–3C). Furthermore, out of a panel of 9 classical HIF target
genes induced by hypoxia in U251MG cells, hypoxic induction of
5 genes (MXI1, BNIP3, ADM, BHLHE40, andNDRG1) was signif-
icantly inhibited by TAPI-2, whereas other genes (PGK1,GLUT1,
CAIX, and VEGF) were largely unaffected by treatment (Fig-
ure 3D). We next performed western blot analysis of HIF-1a
and HIF-2a after TAPI-2 treatment of U251MG cells grown at
normoxia or hypoxia to test whether the diminished hypoxic
response was due to HIF protein level regulation. We found
significantly reduced stabilization of HIF-2a, but not HIF-1a, after
TAPI-2 treatment, indicating that the reduced HIF activity is
mediated by reduced stabilization of HIF-2a (Figure 3E).
Similarly, TMI 1 and GI 254023X reduced HIF-2a protein levels
at hypoxia (Figure S3). Notably, the Notch intracellular domain,
another ADAM10/17-dependent ICD inhibited by TAPI-2, failed
to affect HRE activation in glioma cells (Figure S3A), indicating
that these effects were unrelated to Notch signaling.
CD44ICD Enhances HIF-2a Specifically via Protein-
Protein Interaction
To further elucidate the mechanism underlying HIF-2a stabiliza-
tion by CD44ICD, we used two inhibitors of the proteasomal HIF
Figure 1. Enhanced Intracellular CD44 at Hypoxia in Glioma In Vivo and In Vitro
(A) Immunofluorescent staining of PDGFB-induced murine gliomas in PVN (left) and PN areas (middle) (CD44, green; nestin, red; DAPI, blue). Immunofluores-
cence of PN areas (right) (CD44, green; CAIX, red; DAPI, blue). A minimum of 3 regions per tumor from at least 3 independent tumors were analyzed. Scale bars
represent 50 mm.
(B and C)Western blot of CD44 and actin in PIGPC (B) and U251MG (C) cells grown for 24 hr at 21%or 1%O2, treated as indicated with 10 mMDAPT, 200 mMTPA
(positive control for CD44ICD), or 200 mM TPA with 10 mM DAPT (negative control for CD44ICD). CD44EXT is CD44 cleaved extracellularly but still membrane
bound. Right graph shows quantification of CD44ICD signal across three independent experiments. *p < 0.05; **p < 0.01 (Student’s t test).
(D) Immunofluorescent staining of U251MG cells grown at 21% or 1% O2 for 24 hr for C-terminal CD44 (green) and DAPI (blue). Scale bars represent 20 mm.
Middle panel shows representative pictures of quantification of CD44 staining intensity, where cells are divided into 6 fractions from cell membrane to nucleus.
The bottom panel represents CD44 staining intensity in membrane and cell fractions at 21% or 1% O2, respectively. Data are presented as integrated intensity
(IxA). ns, not significant; ***p < 0.001 (Student’s t test; n = 204 [normoxia], n = 153 [hypoxia]). Data represent one of three independent experiments.
(E) Immunofluorescent staining of PDGFB-induced murine gliomas for C-terminal CD44 (green) and DAPI (blue) in PN tumor areas. A minimum of 3 regions per
tumor from at least 3 independent tumors were analyzed. Scale bars represent 50 mm.
In (B)–(D), error bars represent SEM.
See also Figure S1.
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Figure 2. ADAM17 Expression Is Induced at Hypoxia in Glioma, and ADAM Inhibition Blocks CD44 Cleavage
(A) Western blot of ADAM10, ADAM17 (top band, pro-ADAM; bottom band, mature-ADAM) and actin in U251MG cells grown for 24 hr at 21% or 1% O2. Right
graph shows quantification of pro- and mature ADAM10 and ADAM17 signal across three independent experiments. *p < 0.05 (Student’s t test).
(B) qPCR data for relative mRNA expression of ADAM10 and ADAM17 in U251MG cells cultured at 21% or 1%O2 for the indicated time periods. Data represent
mean values from at least three independent experiments. ns, not significant; *p < 0.05 (Student’s t test).
(C) Immunofluorescent staining of PDGFB-induced murine gliomas (CD44, green; ADAM17, red; DAPI, blue). A minimum of 3 regions per tumor from at least
3 independent tumors were analyzed. Scale bars represent 50 mm.
(D) Relative mRNA expression of ADAM17 in microdissected pseudopalisading versus cellular tumor cells from the Ivy GAP RNA-sequencing data (Allen Institute
for Brain Science Ivy Glioblastoma Atlas Project; http://glioblastoma.alleninstitute.org). p < 0.01 (Tukey’s honest significant difference).
(legend continued on next page)
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degradation pathway. 2,20-dipyridyl (DIP) inhibits prolyl hydrox-
ylation of HIFs and thereby recognition by von Hippel-Lindau
(VHL), and MG132 is a direct proteasome inhibitor. In the pres-
ence of either inhibitor, TAPI-2 no longer had any effect on
HIF-2a protein levels at hypoxia (Figure 4A), suggesting that
ADAM substrates enable HIF-2a to escape the canonical HIF
degradation pathway.
We next employed a set of HIF-amutant constructs (HIF-1 2M,
HIF-2 2M, and HIF-1 3M) mutated either at the PHD hydroxyl-
ation sites (2M constructs) or at the PHD and factor inhibiting
HIF 1 (FIH-1) hydroxylation sites (3M) (Figure 4B). In line with
the decreased HIF-2a protein levels in TAPI-2-treated cells (Fig-
ure 3E), we found decreased HRE-luciferase activation in TAPI-2
treated cells transfected to express anO2-insensitive HIF-2a, but
not HIF-1a (Figure 4C). Similarly, CD44ICD overexpression
significantly enhanced HRE-luciferase activity of cells express-
ing HIF-2 2M, but not HIF-1 2M (Figure 4D). As this potentiation
of HRE activation by CD44ICD was previously found to be
dependent on CREB-binding protein (CBP)/p300 (Pietras et al.,
2014), and as HIF-2a is less sensitive to FIH-mediated hydroxyl-
ation than HIF-1a (Bracken et al., 2006; Yan et al., 2007), we
tested whether a HIF-1a mutant insensitive to FIH-mediated
hydroxylation (and thus FIH-mediated inhibition of HIF-1a/
CBP/p300 interactions at normoxia) (HIF-1 3M) would mimic
the results of HIF-2a overexpression. Strikingly, HIF-1 3M
displayed the same enhanced HRE activation by CD44ICD
as HIF-2 2M (Figure 4D). We next performed co-immunopre-
cipitation using these HIF-a constructs together with an
EGFP-CD44ICD construct in cultured U251MG glioma cells.
Interestingly, EGFP-CD44ICD interacted directly with HIF-2
2M, but not HIF-1 2M, as demonstrated by immunoprecipitating
both hemagglutinin (HA) (for the HIF constructs) and EGFP (for
CD44ICD) (Figure 4E). Again, HIF-1 3M could mimic the effects
of HIF-2 2M and bound directly to CD44ICD (Figure 4E). To
further test the involvement of FIH-1 in the differential regulation
of HIF-1a versus HIF-2a byCD44, we used siRNA to knock down
FIH-1 expression. Interestingly, both HIF-1 2M and HIF-2 2M
constructs were able to bind CD44ICD in cells with FIH-1 levels
knocked down, whereas only HIF-2 2M was able to bind in
siControl transfected cells (Figure 4F). These data demonstrate
differential regulation of HIF-1a versus HIF-2a specifically in
CD44-expressing tumor cells and highlight FIH-1 as a central
factor in differential regulation of HIF-1a versus HIF-2a.
CD44 Is Associated with Hypoxic and Pseudo-Hypoxic
GBM Phenotypes
We next co-stained murine PDGFB-induced GBM tumors for
CD44 and HIF-1/2a. HIF-1a expression overlapped with CD44
in PN tumor areas but was undetectable in the PVN (Figure 5A).
HIF-2a expression overlapped entirely with CD44 expression,(E) Western blot of ADAM17 and actin in U3065MG cells grown for 24 hr at 21% o
HIF2A, respectively. Bottom panel shows quantification of the ADAM17 signal a
t test).
(F) Western blot of CD44 and actin in U251MG cells treated for 24 hr as indicat
representative experiment out of three independent experiments.
In (A), (B), (D), and (E), error bars represent SEM.
See also Figure S2.with intense staining both in the hypoxic PN and well-vascular-
ized PVN areas (Figure 5B). These data suggest that CD44 can
contribute to a pseudo-hypoxic phenotype of stem-like PVN
glioma cells by interacting with and stabilizing HIF-2a. To test
this hypothesis, we cultured U251MG cells at 21%O2 (normoxia)
or 5% O2 (an estimation of the physiological PVN O2 tension),
treated or not with TAPI-2 to inhibit CD44 cleavage. Interestingly,
HIF-2a protein was stabilized at 5% O2 and inhibited by TAPI-2
treatment (Figure 5C). Furthermore, CD44ICD overexpression
was sufficient to induce significant HRE-dependent luciferase
activation in U251MG cells at 5%O2 (Figure 5D). Together, these
data suggest that CD44 expression and activation can enhance
hypoxic and pseudo-hypoxic signaling in glioma in vivo at O2
tensions relevant to both PN and PVN tumor areas.
We next employed a gene signature representative of a clas-
sical hypoxic response and applied it to analyze the human
GBM dataset from TCGA (Brennan et al., 2013). In line with pos-
itive regulation of HIF signaling by CD44ICD, we found a positive
correlation between a signature consisting of CD44/ADAM
expression and the hypoxia gene signature (R = 0.638;
p < 4.33e19) (Figure 5E). Furthermore, dividing tumor samples
by GBM subtype revealed that CD44/ADAM expression largely
follows the hypoxia signature, with highest CD44/ADAM expres-
sion as well as hypoxic drive in mesenchymal tumors and lowest
expression in G-CIMP tumors (Figure 5F). These data support a
role for CD44 cleavage in enhancing hypoxia signaling in human
GBM in vivo.
Targeting ADAMs Reduces Glioma Stemness at Hypoxia
We next tested whether pharmacological inhibition of ADAM10/
17 could decrease stem cell characteristics of hypoxic glioma
cells. First, PIGPCs were subjected to the side population (SP)
assay (Bleau et al., 2009; Golebiewska et al., 2013; Wee et al.,
2016). The SP of PIGPCs cultured at hypoxia, but not normoxia,
was significantly reduced by ADAM inhibition by TAPI-2, TMI 1,
or GI 254023X treatment (Figure 6A). We assessed stemness
of U251MG cells further by measuring a panel of stem cell
marker genes (NANOG, OCT4, and SOX2) by real-time qPCR
and found significantly reduced expression of NANOG, OCT4,
and SOX2 after TAPI-2 treatment of cells grown in hypoxia (Fig-
ure 6B). Furthermore, we assessed self-renewal by sphere for-
mation in human primary GBM U3065MG cells from the Human
Glioblastoma Cell Culture Resource (HGCC) project (Xie et al.,
2015) and found that blocking ADAM10/17 activity affected the
size of the spheres; TAPI-2-treated spheres were significantly
smaller than control spheres (Figure 6C). TAPI-2 treatment did
not affect cell proliferation under adherent conditions (Figure S3).
To directly test the involvement of CD44 in the response to
ADAM inhibition in stemness, we set up the same sphere-forma-
tion experiment in U3065MG cells treated with control or siRNAr 1%O2 expressing control, non-targeting siRNA or siRNA targeting HIF1A and
cross three independent experiments. ns, not significant; *p < 0.05 (Student’s
ed with TAPI-2 (top), GI 254023X (middle), or TMI 1 (bottom). Data show one
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Figure 3. ADAM Inhibition Modulates the Hypoxic Response by Regulating HIF-2a, but Not HIF-1a
(A–C) HRE-luciferase normalized to Renilla for U251MG (A), T98G (B), and PIGPC (C) cells pre-treated with 20 mM TAPI-2 for 24 hr following 48-hr treatment at
21% or 1%O2. Top graphs represent one representative experiment, and error bars represent SD. Bottom graphs represent data normalized to control from four
independent experiments, and error bars represent SEM. *p < 0.05; ns, not significant (Mann-Whitney test).
(D) qPCR data for relative mRNA expression ofMXI1, BNIP3, PGK1,GLUT1, ADM, BHLHE40 NDRG1, and VEGF in U251MG cells treated with 20 mMTAPI-2 and
cultured at 21% or 1% O2. Data represent mean values from at least three independent experiments. *p < 0.05; ns, not significant (Student’s t test).
(E) Western blot analysis of HIF-1a, HIF-2a, and SDHA in U251MG cells grown at 21% or 1%O2 for 24 hr or 72 hr, treated with 20 mM TAPI-2. Right panel shows
quantification of HIF-1a and HIF-2a signal across three independent experiments. ns, not significant; **p < 0.01; ***p < 0.01 (Student’s t test).
In (D) and (E), error bars represent SEM.
See also Figure S3.targeting CD44. In agreement with TAPI-2 treatment acting
through inhibition of CD44 cleavage, data showed that CD44
knockdown reduced sphere size to a similar degree as TAPI-2
treatment of control or control siRNA-treated cells (Figure 6D).
Most importantly, TAPI-2 treatment could not further reduce
sphere size in cells lackingCD44 expression (Figure 6D), strongly1646 Cell Reports 20, 1641–1653, August 15, 2017suggesting that TAPI-2-mediated effects are dependent on inhi-
bition of CD44 cleavage.
We finally extended our analysis to include primary glioma
cultures from different molecular subtypes: U3035 and U3065
(both mesenchymal), U3082 (proneural), and U3084 (classical)
(Xie et al., 2015). As expected from bioinformatic analyses
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Figure 4. CD44ICD Interacts Specifically with HIF-2a, but Not HIF-1a
(A) Western blot analysis of HIF-2a and SDHA in U251MG cells grown at 1%O2 for 24 hr, treated as indicated with 20 mMTAPI-2, 200 mMDIP, and 10 mMMG132.
Data show one representative experiment out of three independent experiments.
(B) Schematic of the HIF mutants used in the study. The basic-helix-loop-helix (bHLH), Per-Arnt-Sim (PAS), N-terminal transactivation domain (NTAD), and
C-terminal transactivation domain (CTAD) are indicated by boxes. The Pro402-to-Ala, Pro564-to-Ala, Pro405-to-Ala, Pro531-to-Ala, and Asn813-to-Ala
substitutions are indicated.
(C) HRE-luciferase normalized to Renilla for T98G cells pretreated 24 hr with 20 mMTAPI-2 expressing pCDNA control, pCDNAHIF-1A-2M, or pCDNAHIF-2A-2M.
Data represent mean values from at least three independent experiments and are normalized to control. *p < 0.05; ns, not significant (Mann-Whitney test).
(D) HRE-luciferase normalized to Renilla for U251MG cells expressing pEGFP control or pEGFP-CD44ICD together with pCDNA control, pCDNAHIF-1A-2M,
pCDNAHIF-1A-3M, or pCDNAHIF-2A-2M. Data represent mean values from at least three independent experiments and are normalized to pEGFP control.
*p < 0.05; ns, not significant (Mann-Whitney test).
(E) Co-immunoprecipitation of EGFP-CD44ICD together with HA-tagged pCDNAHIF-1A-2M, pCDNAHIF-1A-3M, or pCDNAHIF-2A-2M in U251MG cells. Data
show one representative experiment out of three independent experiments.
(F) Co-immunoprecipitation of EGFP-CD44ICD together with HA-tagged pCDNAHIF-1A-2M or pCDNAHIF-2A-2M in U251MG cells expressing siRNA targeting
control or HIF1AN (gene encoding FIH-1) as indicated. Data show one representative experiment out of three independent experiments.
In (C) and (D), error bars represent SEM.(Figure 5F), the two mesenchymal lines displayed higher basal
CD44 protein levels than the proneural and classical lines (Fig-
ure 7A). We tested whether the decrease in stem cell character-istics by ADAM inhibition (Figure 6) was accompanied by induc-
tion of neuronal and/or astrocytic differentiation. All four primary
cultures responded to some extent to ADAM inhibition withCell Reports 20, 1641–1653, August 15, 2017 1647
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Figure 5. CD44 Modulates Hypoxic and
Pseudo-Hypoxic Phenotypes in GBM In Vivo
(A and B) Immunofluorescence of PDGFB-induced
murine gliomas in PVN (left) and PN areas (right)
(CD44, green; HIF1, magenta [A]; HIF2, magenta
[B]; DAPI, blue). A minimum of 3 regions per tumor
from at least 3 independent tumors were analyzed.
Scale bars represent 50 mm.
(C) Western blot of HIF-2a and SDHA in U251MG
cells grown for 72 hr at 21% or 5% O2 and treated
with 20 mM TAPI-2. Right panel shows quantifica-
tion of HIF-2a signal across three independent
experiments HIF-2a. **p < 0.01 (Student’s t test).
(D) HRE-luciferase normalized to Renilla for
U251MG cells expressing pEGFP control or
pEGFP-CD44ICD at 21% or 5% O2. Data repre-
sent mean values from three independent experi-
ments. ns, not significant; *p < 0.05 (Student’s
t test).
(E) Scatterplot of hypoxic signature score (x axis)
against gene expression levels of CD44/ADAM
signature score (y axis) in 155 glioblastoma sam-
ples from TCGA repository. Pearson correlation
coefficients (R) and p values are provided.
(F) Boxplots of CD44/ADAM expression (left) and
expression of hypoxic signature score (right) in
glioblastomas stratified by molecular subclass:
classical (n = 40), G-CIMP (n = 8), mesenchymal
(n = 49), neural (n = 26), and proneural (n = 31).
In (C) and (D), error bars represent SEM.significantly increased protein levels of astrocytic (GFAP) or
neuronal (Tuj1) markers at hypoxia (Figure 7B). Notably, the
two mesenchymal lines with the highest CD44 expression dis-
played a stronger induction of both differentiation markers than
the proneural and classical line (Figure 7B).
DISCUSSION
Differential regulation of HIF-1a versus HIF-2a by O2 and time has
been previously reported (Holmquist-Mengelbier et al., 2006), as1648 Cell Reports 20, 1641–1653, August 15, 2017well as apparent differential regulation of
HIFs in stem-like versus bulk tumor cells
(Heddleston et al., 2009; Li et al., 2009).
Nevertheless, relatively fewunderlyingmo-
lecular mechanisms have been described.
Any model of differential HIF regulation
in GBM in vivo must take into account
that O2 levels alone cannot sufficiently
explain the observed expression patterns
described here, as HIF-2a is expressed in
the most (PVN) and least (PN) oxygenated
tumor areas, but not in tumor bulk (HIF-1a
is expressed only in PN areas). One key
molecular difference between these HIF-a
subunits is the differential sensitivity to
FIH-1-mediated asparagine hydroxylation;
HIF-1a is significantlymoresensitive to this
modification than HIF-2a (Bracken et al.,
2006; Yan et al., 2007). Hydroxylation byFIH inhibits HIF-a binding to its co-factors CBP and p300, repre-
senting an additional layer of O2-dependent regulation apart
from prolyl hydroxylation. We and others have previously demon-
strated thatCD44ICD-mediated transcriptional effects are depen-
dent on CBP and p300 (Okamoto et al., 2001; Pietras et al., 2014).
In light of these data, we speculated that the differential regulation
of HIF-1a versus HIF-2a by CD44ICD was dependent on FIH-
mediated hydroxylation. This could be of particular interest, as
HIF-2a, but notHIF-1a, is stabilized specifically in the non-hypoxic
PVN, where FIH-mediated hydroxylation would be involved in HIF
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Figure 6. ADAM Inhibition Blocks Stemness in Hypoxic Glioma Cells
(A) Side population assay of PIGPC cells pretreated with 20 mM TAPI-2, 0.5 mM TMI1, and 1 mM GI 254023X, respectively, grown at 21 or 1% O2 for 48 hr. Right
graphs show quantification across three independent experiments. *p < 0.05, **p < 0.01; ns, not significant (Student’s t test).
(B) qPCRdata for relativemRNA expression ofNANOG,OCT4, andSOX2 in U251MGcells treatedwith 20 mMTAPI-2 and grown in 21%or 1%O2. Data represent
mean values from at least three independent experiments. *p < 0.05; ns, not significant (Student’s t test).
(C) Sphere-formation assay with U3065MG cells treated with 20 mM TAPI-2 at 21% or 1% O2. Bottom panel shows quantification of relative sphere area from
three independent experiments. Scale bars represent 100 mm, and error bars represent SEM. *p < 0.05, ***p < 0.001 (Mann-Whitney test).
(D) Sphere-formation assay with U3065MG cells expressing control or siRNA targeting control or CD44 treated with 20 mM TAPI-2 at 21% or 1% O2. Scale bars
represent 100 mm. Right panel shows quantification of relative sphere area, where error bars represent SEM. ns, not significant; **p < 0.01, ***p < 0.001 (Student’s
t test).
In (A) and (B), error bars represent SEM. See also Figure S4.regulation. Indeed, we found that the potentiation of HRE-activa-
tion by HIF-2a by CD44ICD, as well as the binding of CD44ICD
toHIF-2a, could be replicatedwith HIF-1a if the FIH-hydroxylation
site of HIF-1a was mutated or if FIH-1 expression was knocked
down. In light of these findings, special care should be taken
when interpreting biological data generated with FIH-insensitive
HIF-1amutant constructs.Our data are consistent with a model where HIF-2a is specif-
ically expressed in the PVN due to the specific expression of
the stem cell marker CD44 in the PVN. Since the enhanced HIF
activity resulting from CD44ICD expression is dependent on
CBP/p300 binding to HIF, this effect is impaired for HIF-1a
due to FIH-mediated hydroxylation of PVN HIF-1a (but not
HIF-2a) (Figure 7C). These findings have implications for ourCell Reports 20, 1641–1653, August 15, 2017 1649
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Figure 7. ADAM Inhibition Induces Expression of Differentiation Markers in CD44+ Primary Glioma Cells at Hypoxia
(A) Western blot of CD44 and actin in U3035MG, U3065MG, U3082MG, and U3084MG cells grown at 21% O2. Data show one representative experiment out of
three independent experiments.
(B) Immunofluorescent staining of U3035MG, U3065MG, U3082MG, andU3084MGcells treatedwith 20 mMTAPI, 0.5 mMTMI 1, or 1 mMGI 254023X and cultured
at 1% O2 for 7 days (GFAP, red; Tuj1, green; DAPI, blue). Scale bars represent 50 mm. Right panel shows quantification of relative intensity of GFAP and Tuj1
staining to control normalized to number of nuclei per field. Data are presented as mean of three independent experiments. Error bars represent SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 (Student’s t test).
(C) Proposed model of ADAM/CD44-dependent regulation of hypoxic and pseudo-hypoxic glioma phenotypes.understanding of several observations:Why is HIF-2a expressed
at high levels in perivascular and well-oxygenated tumor areas
(Holmquist-Mengelbier et al., 2006; Li et al., 2009; Pietras
et al., 2014)? Why do stem-like tumor cells have a pseudo-hyp-
oxic phenotype at normoxia and an enhanced hypoxic response1650 Cell Reports 20, 1641–1653, August 15, 2017at hypoxia (Bar et al., 2010; Li et al., 2009; Pietras et al., 2008,
2010, 2014)? A model where expression and activation of a
stem cell marker like CD44 can directly impact HIF-2a stabiliza-
tion has the potential to explain this differential HIF regulation in
stem-like versus bulk glioma cells.
Therapeutic targeting of transcription factors such as HIFs is
notoriously difficult, and although both HIF-1a and HIF-2a have
been described as prime potential therapeutic targets in many
solid tumors, few successful attempts have been reported
(Cho and Kaelin, 2016). Our data open for the possibility of
targeting HIF-2a specifically in the PVN by targeting the cell-
surface-expressed, druggable CD44 receptor. There are
several ways in which such inhibition could conceivably
work: inhibition of CD44-ligand interactions by blocking anti-
bodies, inhibition of external cleavage of CD44 (as reported
here), or inhibition of internal CD44 cleavage using gamma-
secretase inhibitors. Our data suggest that stem cell charac-
teristics and parts of the general hypoxic response can be
successfully targeted using the approach of targeting
ADAM10/17-dependent CD44 cleavage. Further research is
warranted to test whether these effects are sufficient to affect
treatment resistance of PVN glioma cells.
EXPERIMENTAL PROCEDURES
Generation of Murine Gliomas
Gliomas were induced in Nestin-tv-a (Ntv-a) Ink4a/Arf/ mice by injecting
RCAS-PDGFB and RCAS-shp53-transfected DF-1 cells (ATCC) intracranially
in the neonatal brain as previously described (Holland et al., 1998; Ozawa
et al., 2014). Mice were monitored daily and euthanized upon symptoms of gli-
oma. All animal procedures were approved by the Malmo¨-Lund Ethical Com-
mittee (permit M186-14), and the use of laboratory animals was conducted in
accordance with European Union directive on the subject of animal rights.
Immunofluorescence
Cryosections from PDGFB-induced murine gliomas were fixed in acetone and
permeabilized in PBS containing 0.3% Triton X-100 (Sigma). Sections were
blocked for 30 min in serum-free protein block (DAKO, Gostrup, Denmark)
and incubated with the following primary antibodies (4C overnight): HIF-1a
(Novus Biologicals NB100-479), HIF-2a (Abcam ab199), CD44 (BD Biosci-
ences 550538), C-terminal CD44 (Abcam ab157107), nestin (BD Biosciences
556309), HIF-1a (Novus Biologicals NB100-479), HIF-2a (Abcam ab199,
Dako), CAIX (R&D Systems AF2344), ADAM17 (LSbio LS-B619-50), Tuj1 (Bio-
Legend 801201) or GFAP (Dako Z0334) (diluted in antibody diluent with Back-
ground Reducing Components; DAKO, Gostrup, Denmark) followed by
washing and incubation with EnVision FLEXMOUSE (linker) DM824 combined
with subsequent incubation with mouse immunoglobulin G (IgG) made in rab-
bit 1:600 (ab125907) in antibody diluent (DM830, DAKO), or EnVision FLEX
RABBIT (linker DM825, DAKO). After washing, sections were incubated with
Alexa Fluorchrome 488 and 546 (Invitrogen) followed by washing and
mounting in Vechtashield Hard Set with DAPI (Vector Laboratories, Burlin-
game, CA). Images were acquired using an Olympus BX63 microscope
and DP80 camera and cellSens Dimension v 1.12 software (Olympus
Corporation).
Quantification of Staining
GFAP and Tuj1 staining was quantified using ImageJ by setting an intensity
threshold. Intensity was normalized to the number of nuclei per field. The
following list shows the total number of cells analyzed per sample:
U3065MG: 21%O2, control (Ctrl) n = 1,496; 21% O2, TAPI-2 n = 140; 21%
O2, GI254023X n = 716; 21%O2; TMI1 n = 1231; 1%O2, Ctrl n = 1,084; 1%
O2, TAPI-2 n = 315; 1% O2, GI254023X n = 779; 1% O2, TMI1 n = 1,319
U3088MG: 21% O2, Ctrl n = 770; 21% O2, TAPI-2 n = 314 ;21% O2,
GI254023X n = 487; 21% O2, ; TMI1 n = 740; 1% O2, Ctrl n = 239; 1%
O2, TAPI-2 n = 232; 1% O2, GI254023X n = 493; 1% O2, TMI1 n = 239
U3084MG: 21% O2, Ctrl n = 174; 21% O2, TAPI-2 n = 131 ;21% O2,
GI254023X n = 92; 21% O2; TMI1 n = 184; 1% O2, Ctrl n = 103; 1% O2,
TAPI-2 n = 308; 1% O2, GI254023X n = 109; 1% O2, TMI1 n = 198U3082MG: 21% O2, Ctrl n = 370; 21% O2, TAPI-2 n = 601; 21% O2,
GI254023X n = 230; 21% O2; TMI1 n = 859; 1% O2, Ctrl n = 167; 1% O2,
TAPI-2 n = 153; 1% O2, GI254023X n = 430; 1% O2, TMI1 n = 166
U3035MG: 21% O2, Ctrl n = 176; 21% O2, TAPI-2 n = 415; 21% O2,
GI254023X n = 263; 21% O2; TMI1 n = 332; 1% O2, Ctrl n = 560; 1% O2,
TAPI-2 n = 405; 1% O2, GI254023X n = 110; 1% O2, TMI1 n = 123
U3046MG: 21% O2, Ctrl n = 489; 21% O2, TAPI-2 n = 230; 21% O2,
GI254023X n = 482; 21% O2; TMI1 n = 290; 1% O2, Ctrl n = 209; 1% O2,
TAPI-2 n = 390; 1% O2, GI254023X n = 31; 1% O2, TMI1 n = 167
CD44 C-terminal staining was quantified using CellProfiler (Carpenter et al.,
2006) (http://cellprofiler.org). DAPI staining was used for segmentation of
nuclei, and CD44 staining was used for segmentation of cells. Intensity for
the total cell and for the edge was calculated. Heatmaps were generated illus-
trating the fraction of the radial distribution of the total stain in each of 6 bins in
each cell.
Cell Culture, Hypoxia, and Reagents
PIGPC cells were isolated as previously described (Pietras et al., 2014).
U251MG and T98G cells were obtained from ATCC. PIGPC, U251MG, and
T98G cells were grown in DMEM (Life Technologies) supplemented with
10% fetal bovine serum (FBS) and 1% PenStrep solution. Hypoxia was gener-
ated inWhitney H35Hypoxiastation (DonWhitley Scientific). Cells were treated
with 200 mM DIP (Sigma), 1,6 mM TPA (Sigma), 20 mM TAPI-2 (Sigma), 0.5 mM
TMI1 (Tocris Bioscience), and 1 mMGI 254023X (Tocris Bioscience) and 10 mM
MG132 (Sigma). Plasmids were transfected using Xtreme gene 9 (Roche)
and siRNAs using HiPerFect (QIAGEN) according to the manufacturer’s
instructions.
siRNAs, non-targeting (D-001810-01-20) HIF1A (LQ-004018-00-0002),
HIF2A (LQ-004814-00-0002), CD44 (J-009999-07), and FIH1 (CTM-305836)
were from GE Dharmacon. U3035MG, U3065MG, U3082MG, and U3084MG
primary glioma cells were obtained from HGCC (http://hgcc.se) and cultured
as described previously (Xie et al., 2015) in 1:1 Neurobasal (GIBCO) and
DMEM/F12 with Glutamax (Life Technologies) media supplemented with 1%
PenStrep, N2, B27 (both from Life Technologies), epidermal growth factor
(EGF), and fibroblast growth factor (FGF) (20 ng/mL) (both from Peprotech).
Cells were grown to subconfluence, dissociated by Accutase (Thermo Fisher
Scientific), and grown ether as neurospheres or as a monolayer on polyorni-
thine- (Sigma) and laminin-coated (Biolamina) plastic.
Western Blot and Co-immunoprecipitation
Cells were lysed in buffer containing 20 mM Tris (pH 8), 150 mM NaCl, 1 mM
EDTA, and 0.5% NP40 following co-immunoprecipitation using Dynabeads
protein G (Invitrogen) according to the manufacturer’s instructions. For west-
ern blots, cells were lysed in RIPA buffer supplemented with Complete prote-
ase inhibitor cocktail (Roche). The following antibodies were used: C-terminal
CD44 (Abcam ab157107), HIF-1a (Novus Biologicals NB100-479), HIF-2a
(Abcam ab199), SDHA (Abcam ab14715), actin (Abcam ab75186), HA (Milli-
pore 04-902 and Abcam ab9110), GFP (Abcam ab290 and Abcam
ab38689), ADAM10 (Abcam ab1997), ADAM17 (LSbio LS-B619-50), HIFAN
(Abcam ab187524). All data represent at least three independent experiments.
Real-Time qPCR
RNA was isolated in using the RNeasy Mini Kit together with the Qiashredder
Kit (QIAGEN), and cDNA was synthesized using random primers and Multi-
Scribe reverse transcriptase enzyme (Applied Biosystems). The amplifications
were run using a QuantStudio 7 real-time PCR system (Applied Biosystems)
with SYBR Green Master Mix (Applied Biosystems). Relative gene expression
was normalized to the expression of three housekeeping genes (UBC, SDHA,
andYWHAZ) using the comparative Ctmethod (Vandesompele et al., 2002). All
detections were performed in triplicate using the following primers: ADM
(human) forward (f): 50-CACATGATTCTGGAACAGAG-30, reverse (r): 50-GTTG
TTAAGTTTGTCCCCAG-30; ADAM10 (human) f: 50-CACATGATTCTGGAA
CAGAG-30 r: 50-GTTGTTAAGTTTGTCCCCAG-30; ADAM17 (human) f: 50-CCA
TAGCTGTGAGTGGCGAT-30 r: 50-TGGGCCTTACTTTCAATGGTCT-30; BNIP3
(human) f: 50-AAAATATTCCCCCCAAGGAGTTC-30, r: 50-ACGCTCGTGTT
CCTCATGCT-30; CD44 (human) f: 50-TGGCATCCCTCTTGGCCTTGG-30,Cell Reports 20, 1641–1653, August 15, 2017 1651
r: 50-TGAGACTTGCTGGCCTCTCCGT-30; Cd44 (mouse) f: 50- TCGTTGCCC
TTCTCCCCACGA-30, r: 50-CCTGCGTAGCGGCAGGTTACA-30; BHLHE40 (hu-
man) f: 50-CAGTGGCTATGGAGGAGAATCG-30, r: 50-GCGTCCGTGGTCAC
TTTTG-30; MXI1(human) f: 50-AGAGGAGATTGAAGTGGATG-30, r: 50-CTGGGT
TCTATGAAGTGAATG-30; NANOG (human) f: 50-GCTGGTTGCCTCATGTT
ATTATGC-30, r: 50-CCATGGAGGAAGGAAGAGGAGAGA-30; OCT4 (human)
f: 50-AGCAAAACCCGGAGGAGT-30, r: 50-CCACATCGGCCTGTGTATATC-30;
SDHA (human) f: 50-TGGGAACAAGAGGGCATCTG-30, r: 50-CCACCACTG
CATCAAATTCATG-30; Sdha (mouse) f: 50- CTTGAATGAGGCTGACTG-30, r:
50- ATCACATSSGCTGGTCCTG-30; SOX2 (human) f: 50- GCCTGGGCGCC
GAGTGGA-30, r: 50- GGGCGAGCCGTTCATGTAGGTCTG-30; UBC (human) f:
50- ATTTGGGTCGCGGTTCTT-30, r: 50- TGCCTTGACATTCTCGATGGT-30;
Ubc (mouse) f: 50- AGCCCAGTGTTACCACCAA 30, r: 50- ACCCAAGAACA
AGCACAA-30; YWHAZ (human) f: 50-ACTTTTGGTACATTGTGGCTTCAA-30,
r: 50- CCGCCAGGACAAACCAGTAT 30; Ywhaz (mouse) f: 50-CAGTAGATG
GAGAAAGATTTGC-30, r: 50-GGGACAATTAGGGAAGTAAGT-30.
Side Population Assay
For SP, cells were resuspended at 1 3 106 cells/mL and incubated at 37C,
30 min with or without fumitremorgin C (FTC) (Sigma). Cells were incubated
for a further 90 min with 5 mg/mL Hoechst 33342 (Sigma) with periodic
shaking. Cells were analyzed on an FACSVerse instrument (BD) equipped
with a 405-nm violet laser. Dual-wavelength detection was performed using
448/45 (Hoechst 33342-blue) and 613/18 (Hoechst 33342-red) filters. Data
were analyzed using FlowJo software.
Luciferase Assays and Plasmids
For the luciferase reporter assay, cells were co-transfected with HRE-luc
(Emerling et al., 2008) (a gift from Navdeep Chandel, Addgene 26731) and
pCMV-renilla (Promega) and then analyzed for luciferase using the Dual-Lucif-
erase Reporter Assay System (Promega) on a Synergy 2 plate reader (BioTek).
The human pEGFP-CD44ICD plasmid was previously described (Pietras et al.,
2014). pcDNA3 was from Invitrogen. The human Notch1-ICD plasmid was a
kind gift from J.C. Aster (Aster et al., 1997). pEGFP-C1 was from Clontech
Laboratories. O2-insensitive mutants of HIF1A (HIF-1A-2M) and HIF2A (HIF-
2A-2M) were a gift from William Kaelin (Addgene plasmids 18955 and
18956, respectively) (Emerling et al., 2008; Yan et al., 2007). O2-insensitive
mutant HIF-1A-3M was generated by site directed mutagenesis of Asn803
to- Ala from the HIF1A using QuickChange Lightning Site Specific Mutagen-
esis kit (Agilent). All plasmids were verified by sequencing.
Sphere Formation and Proliferation Assay
For sphere formation, U3065MG cells were plated at single-cell density in
30-mL drops on the lid of a 48-well plate and grown for 7–10 days with
20 mM TAPI-2. Pictures were acquired with an Axio Vert.A1 Zeiss microscope,
and sphere area was measured using ImageJ and presented relative to con-
trol. For proliferation, U3065MG cells were cultured as monolayer cultures in
laminin-coated 6-well plates. 50,000 cells were plated and grown at either
21% or 1% O2, treated with control or 20 mM TAPI-2, and counted in a hemo-
cytometer at the indicated time points.
Bioinformatic Analysis
Level 3 RNA-sequencing data containing mRNA gene-level RNA-seq by
expectation maximization (RSEM) estimates were downloaded from TCGA
data portal https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm by
September 2014. Gene expression levels for were created by multiplying the
gene-level RSEM estimate values by 106 followed by adding an offset of
1 and subsequent log2 transformation. The primary tumor from each patient
was used, resulting in a dataset comprising 155 samples. Hypoxia pathway
activity was estimated for each sample by calculating the mean expression
value for genes within the Broad Molecular Signature Database (MSigDB)
hypoxia hallmark gene set ‘‘HALLMARK_HYPOXIA v5.1’’ (http://software.
broadinstitute.org/gsea/msigdb/index.jsp).
Data from the Allen Institute for Brain Science Ivy Glioblastoma Atlas Project
(available at http://glioblastoma.alleninstitute.org) were analyzed using the
GlioVis data portal for visualization and analysis of brain tumor expression
datasets (Bowman et al., 2017).1652 Cell Reports 20, 1641–1653, August 15, 2017Statistical Analysis
Unless otherwise stated, all values are presented as mean ± SEM from at least
three independent experiments. Statistical significance was calculated using
unpaired, two-sided t tests in GraphPad/Prism. Three levels of significance
were used (*p < 0.05, **p < 0.01, and ***p < 0.01).
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